Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Gains from Investment Securities: 2017-2025

Historic Gains from Investment Securities for UroGen Pharma (URGN) over the last 5 years, with Sep 2025 value amounting to $6.0 million.

  • UroGen Pharma's Gains from Investment Securities rose 2066.34% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 518.31%. This contributed to the annual value of $200,000 for FY2024, which is 80.19% down from last year.
  • UroGen Pharma's Gains from Investment Securities amounted to $6.0 million in Q3 2025, which was up 1,285.58% from $430,000 recorded in Q2 2025.
  • UroGen Pharma's 5-year Gains from Investment Securities high stood at $6.0 million for Q3 2025, and its period low was -$767,000 during Q3 2023.
  • For the 3-year period, UroGen Pharma's Gains from Investment Securities averaged around $640,547, with its median value being $219,000 (2024).
  • As far as peak fluctuations go, UroGen Pharma's Gains from Investment Securities surged by 10,160.00% in 2021, and later slumped by 237.95% in 2023.
  • Over the past 5 years, UroGen Pharma's Gains from Investment Securities (Quarterly) stood at -$553,000 in 2021, then spiked by 148.64% to $269,000 in 2022, then crashed by 104.46% to -$12,000 in 2023, then skyrocketed by 1,925.00% to $219,000 in 2024, then soared by 2,066.34% to $6.0 million in 2025.
  • Its Gains from Investment Securities stands at $6.0 million for Q3 2025, versus $430,000 for Q2 2025 and $883,811 for Q1 2025.